Render Target: STATIC
Render Timestamp: 2024-12-02T11:15:48.746Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-08-01 15:28:09.766
Product last modified at: 2024-08-30T22:30:08.594Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Crry Antibody #44585

Filter:
  • WB

    Supporting Data

    REACTIVITY M
    SENSITIVITY Endogenous
    MW (kDa) 60-80
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Crry Antibody recognizes endogenous levels of total Crry protein.

    Species Reactivity:

    Mouse

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu99 of mouse Crry protein. Antibodies are purified by peptide affinity chromatography.

    Background

    Crry, also known as complement component receptor 1-like protein (Cr1l), is a murine membrane-bound complement regulatory protein ubiquitously expressed in mouse tissues (1,2). Crry is a functional analog of the human complement decay-accelerating factor (DAF/CD55) and membrane cofactor protein (MCP/CD46) (3). In mice, Crry acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissues (4,5). Crry also acts as a decay-accelerating factor, preventing the formation of C4b2a and C3bBb, which are amplification convertases of the complement cascade (3,6). Crry plays a crucial role in early embryonic development by maintaining fetomaternal tolerance (7). On CD4+ T cells, Crry acts as a costimulatory factor which favors IL-4 rather than IFN-gamma secretion, suggesting Th2 polarization (8). Cancer cells and cells of the tumor microenvironment have been shown to overexpress Crry, suppressing tumor-specific T cell responses and complement-mediated anti-tumor immunity (9,10). Multiple isoforms have been identified computationally.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.